Results 1 to 10 of about 13,103,023 (178)
Treatment Adherence to Nucleos(t)Ide Analogs in Chinese Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study [PDF]
Yueyue Li,1,* Anni Chen,2,* Hui Wang,2 Lu Han,1 Rong Wang,1 Guoqing Zhang,2 Yongfang Yuan1 1Department of Pharmacy, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, 200011, People’s Republic of China ...
Yongfang Yuan, Yueyue Li
exaly +4 more sources
GAAD Score as a Prognostic Model for Recurrence of Hepatocellular Carcinoma After Curative Resection
ABSTRACT Hepatocellular carcinoma (HCC) has a high recurrence rate after curative resection. The GAAD score, which combines gender, age, α‐fetoprotein (AFP), and PIVKA‐II, was developed for HCC detection, but its prognostic value after resection remains unclear.
Yueh‐Jen Chung +8 more
wiley +1 more source
Advances in Viral Markers for Predicting Functional Cure of Chronic Hepatitis B
Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) loss, is achieved by only a minority of patients with chronic hepatitis B (CHB); early identification of likely responders may improve cure rates and reduce costs. However, responses to antiviral therapy vary considerably, necessitating reliable hepatitis B virus (HBV) viral ...
Xinrong Lu +3 more
wiley +1 more source
Recompensation of Cirrhosis: A New Treatment‐Related Disease State
This perspective article conceptualizes recompensation of cirrhosis as a distinct treatment‐related disease state rather than mere transient clinical improvement after etiology‐directed therapy, and further proposes a four‐state classification including compensated cirrhosis, stable recompensation, unstable recompensation, and persistent decompensation
Wentao Tan +5 more
wiley +1 more source
This perspective outlines China's contributions toward functional‐cure‐oriented antiviral therapies for chronic hepatitis B, summarizing key clinical data on bepirovirsen and domestic drug pipelines with balanced coverage of both promising and disappointing trial results.
Dandan Weng, Zhujun Cao, Qing Xie
wiley +1 more source
The Impact of Common Medications on Male Fertility: An Updated Systematic Review
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli +7 more
wiley +1 more source
In patients with chronic hepatitis Delta, the LGP2 Q425R variant (rs2074158 CC/CT genotypes), associated with an enhanced interferon response in vitro, becomes progressively less frequent as liver disease advances from no cirrhosis to cirrhosis, and to cirrhosis with progressive increase of portal hypertension evaluated by thrombocytopenia.
Sara Cmet +16 more
wiley +1 more source
One‐year reassessment of type IV collagen 7S, supported by quantitative M2BPGi‐Qt assessment, helped refine long‐term hepatocellular carcinoma risk stratification in patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy. On‐treatment 4COL7S emerged as a novel marker of residual fibrosis‐related HCC risk.
Kazumi Yamasaki +9 more
wiley +1 more source
Clinical Application of Artificial Intelligence in the Management of Chronic Hepatitis B
ABSTRACT Chronic hepatitis B (CHB) burdens the healthcare system, affecting millions of individuals worldwide with a potential progression to complications such as cirrhosis and hepatocellular carcinoma (HCC). The World Health Organization launched the chronic viral hepatitis elimination plan which aimed to eliminate chronic hepatitis B virus by 2030 ...
Jimmy Che‐To Lai +7 more
wiley +1 more source
Hepatitis B in Organ Transplantation—Current Evidence and Clinical Gaps
ABSTRACT Over the past several decades there have been significant advances in nucleos(t)ide analogue (NA) antiviral therapy for hepatitis B virus (HBV) and global expansion of primary prevention through immunization. Despite this, HBV remains a leading cause of chronic liver disease globally, affecting over 250 million people.
Oscar A. Fernandez‐Garcia +3 more
wiley +1 more source

